Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Stanford J, Stewart"'
Autor:
Dennis J. Slamon, Mansoor N. Saleh, Stanford J. Stewart, Joanne E. Mortimer, Andrew Arnold, Debasish Tripathy, Melody A. Cobleigh, M. Murphy
Publikováno v:
Journal of Clinical Oncology. 22:1063-1070
Purpose In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer. We conducted an exte
Autor:
Stanford J. Stewart, Michael Burchmore, Steven Shak, M. Murphy, William Novotny, Dennis J. Slamon, Louis Fehrenbacher, John Gutheil, Lyndsay Harris, Debasish Tripathy, Melody A. Cobleigh, Charles L. Vogel
Publikováno v:
European Journal of Cancer. 37:25-29
Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin(trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer
Autor:
Deborah L. Keefe, Clifford A. Hudis, Stanford J. Stewart, Andrew D. Seidman, Maureen E. Murphy, Mark Ashby, Mary Kathryn Pierri, Virginia E. Paton, Steven Shak
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(5)
PURPOSE: This study sought to estimate cardiac dysfunction (CD) risk for patients receiving trastuzumab; to characterize observed CD by severity, treatment, and clinical outcome; to assess effects of baseline clinical risk factors on CD; and to asses
Autor:
John K. Erban, Kathy D. Miller, Mark D. Pegram, Denise A. Yardley, Elizabeth Tan-Chiu, Seila Liv, Stanford J. Stewart, Hope S. Rugo
Publikováno v:
Journal of Clinical Oncology. 32:TPS671-TPS671
TPS671^ Background: Response to trastuzumab (T)-based chemoimmunotherapy in metastatic breast cancer segregates according to expression of the Fcg receptor, CD16A, allotypes with patients homozygou...
Autor:
Eric C. Vonderheid, Madeleine Duvic, Glen Bowen, Stanford J. Stewart, Patricia Bacha, Arturo Molina, Seth R. Stevens, Brian V. Jegasothy, Youn H. Kim, Lauren C. Pinter-Brown, Arthur E. Frankel, Allan Oseroff, David P. Fivenson, Gary S. Wood, Timothy M. Kuzel, Peter W. Heald, Elise A. Olsen, Ann Martin, Fiona E. Craig, Kevin D. Cooper, Michael Glode, Jean Nichols, Michael S. Gordon, Elizabeth Knobler, James M. Reuben, Francine M. Foss
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(2)
PURPOSE: The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB389IL-2, Ontak [Ligand Phar-maceuticals Inc, San Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymph
Autor:
Howard A. Burris, Todd M. Bauer, Giuseppe Giaccone, Jan Baughman, Seock-Ah Im, Hua Li, Stanford J. Stewart, Jane B. Trepel, David A Carlin, Jeffrey L. Nordstrom, Yung-Jue Bang
Publikováno v:
Journal of Clinical Oncology. 31:3004-3004
3004 Background: The anti-HER2 MAb, trastuzumab (H), has proven effective for HER2+ breast cancer (BC) and gastroesophageal cancer (GEC). H’s mechanism of action is incompletely understood, but evidence indicates ADCC is important. MGAH22 is an Fc-
Autor:
Stanford J. Stewart, Kenneth A. Starling, C. Philip Steuber, Dell A. Shepherd, John M. Falletta
Publikováno v:
Medical and Pediatric Oncology. 3:231-235
Twin girls, genetically identical, probably experienced different leukemogenic events and presented with acute lymphocytic leukemia 6 years apart. Their clinical presentations were similar, but they received significantly different therapy. The first